NovImmune enters exclusive antibody licensing agreement with Genentech

IL-17 signaling pathway has begun to receive significant academic and corporate interest because its manipulation may potentially provide new treatment opportunities for major medical conditions
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PLAN-LES-OUATES, Switzerland—NovImmune, anantibody-focused research and development biotech company, recently entered into an exclusive licensing agreement with GenentechInc. a  member of the Roche Group, for a proprietary anti-IL-17 fully human monoclonalantibody, and access to back-up antibodies.
 
According to the two companies, the IL-17 signalingpathway has begun to receive significant academic and corporate interest because itsmanipulation may potentially provide new treatment opportunities for majormedical conditions.
 
 
The anti-IL-17 antibody was generated by NovImmune'sresearch team and is currently in late preclinical development. Under the termsof the agreement, NovImmune will receive an upfront payment and is eligible toreceive clinical milestones and royalties on sales. Full financial terms have not been disclosed.
 
 
"We believe Genentechis the right partner for NovImmune for this program," says Jack Barbut, CEO of NovImmune. "Genentech brings anin-depth understanding of IL-17 biology and extensive experience in its abilityto potentially identify patient populations that may benefit from such acompound thus maximizing chances of successful development."
 
 
James Sabry, Vice President of GenentechPartnering, adds: "Genentech is very pleased to have the opportunity to workwith NovImmune  on the development and potentialcommercialization of this anti-IL-17 antibody. We are hopeful that it has thepotential to benefit patients across a range of autoimmune diseases."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue